Early-stage biotech Synterica is a early-stage biotechnology company focusing on oral therapeutics for enteric diseases with a novel approach to target pathogenic gut bacteria and their toxins, presenting a sales opportunity around gut health and antibiotic alternative therapeutics.

Toxicity neutralization The primary target is neutralizing toxins from Clostridium difficile, signaling a potential sales angle with hospitals, clinics, and long-term care facilities that manage C. difficile infections and associated costs.

Small team With 0-1 employees, the company is likely seeking strategic partnerships, contract research, or co-development deals, offering an entry point for collaboration and outsourced development services.

Cloud tech stack Usage of AWS, Google Cloud, React, and modern deployment tools indicates a tech-forward organization; potential fit for cloud-based data collaboration, bioinformatics analytics, and secure data sharing platforms.

Funding stage Revenue under $1M and early-stage funding suggest opportunities for grant support, strategic investments, and advisory services, as well as potential for pilot-scale collaborations with larger pharma or biotech partners.